17 April 2020
SpeeDx Blue Sky Research Team Publish Novel Research
SpeeDx is committed to continually improving and innovating diagnostics with ongoing advances spun out of our remarkable Blue Sky Research...
12 February 2020
SpeeDx Raise Additional $15 Million in Series B Funding
SpeeDx today announced it has raised $15 million in additional series B equity investment from U.S.-based Northpond Ventures. This investment...
16 January 2020
SpeeDx and LabCorp Working Together
SpeeDx and LabCorp are working together to develop and introduce new tests with the promise to help improve patient care,...
17 November 2019
Melbourne Sexual Health Continue Success with Resistance Guided Therapy
Mycoplasma genitalium (Mgen) infections treated using resistance guided therapy led to high cure rates and low levels of de novo...
8 November 2019
FIND Collaborate with SpeeDx and QuantuMDx
The Foundation for Innovative New Diagnostics (FIND) are supporting a collaboration with SpeeDx and QuantuMDx to assess the feasibility of...
29 October 2019
TGA Clears ResistancePlus® MG FleXible for Sale in Australia
The Therapeutic Goods Administration (TGA) have cleared ResistancePlus® MG FleXible for the Cepheid GeneXpert® System, and it is now available...
